New and experimental HIV treatments: latest news

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

More news

New and experimental HIV treatments news selected from other sources

  • New HIV therapy reduces virus, boosts immunity in drug-resistant patients

    Ibaluzimab, a CD4 receptor inhibitor and the first monoclonal antibody developed as an anti-HIV drug, was approved for treatment in the US for people with multiply drug-resistant HIV (MDR-HIV) last February. In the results of a phase III study published today, 83% of a group of patients with MDR-HIV achieved an undetectable viral load on ibaluzimab and 50% maintained this over six months. Details of this and another phase III study will be presented later htis year.

    18 hours ago | Science Daily
  • Should Gilead Be Worried About This New Monthly HIV Medication?

    Yesterday, Johnson & Johnson and ViiV Healthcare announced positive results from the Atlas phase 3 study testing their two-drug HIV treatment containing an investigational drug cabotegravir and rilpivirine, a nucleoside reverse transcriptase inhibitor (NRTI) sold by Johnson & Johnson as Edurant. The important thing here isn't going from three medications to two, but that ViiV and Johnson & Johnson's cabotegravir and rilpivirine combination is injected once a month compared to a daily therapy for the three-drug combination.

    20 hours ago | Motley Fool
  • ViiV, Janssen’s two-drug HIV regimen hits PhIII targets

    ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.

    15 August 2018 | Pharma Times
  • How Will Long-Acting HIV Antiretrovirals Work in the Real World?

    While there has been considerable buzz within the HIV workforce about the promise of long-acting antiretrovirals to transform both HIV prevention and treatment, a critical question hangs in the air: Once viable long-acting options have reached the market, what will be their true impact? Will they really help move us toward an HIV-free world?

    01 August 2018 | The Body Pro
  • The 2018 Pipeline Report

    Welcome to the 2018 Pipeline Report, Treatment Action Group’s annual review of therapeutics, diagnostics, vaccines, and preventive technologies in development for HIV, hepatitis C virus (HCV), and tuberculosis, along with immune-based and gene therapies and research toward a cure for HIV.

    24 July 2018 | TAG
  • FDA approves Janssen's HIV combination Symtuza

    Janssen has won US approval for its once-daily HIV pill Symtuza, which combines Janssen’s darunavir with Gilead’s cobicistat, emtricitabine and tenofovir alafenamide in a single pill.

    18 July 2018 | Pharmaphorum
  • Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug

    GILD’s $14 billion annual income stream could be in jeopardy, because they are literally one drug approval away from an armageddon they admit in their 10-K is coming. A small competitor, CytoDyn Inc. has been struggling for over a decade to get PRO 140 approved as a salvage therapy to drug resistant HIV patients. After two successful phase 3 studies (pivotal combination therapy and investigational monotherapy), they are in a position to file a BLA for combination therapy, but the real threat is that the data is so robust that it reduces the viral load to undetectable levels and keeps it there without the help of HAART, the current standard of care.

    18 July 2018 | Seeking Alpha
  • CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial

    Approximately 81% of patients completing PRO 140 trial demonstrated suppressed viral load with plasma HIV-1 RNA viral load of less than 50 copies/ml and 92% had viral load of less than 400 cp/ml.

    17 July 2018 | CytoDyn press release
  • Abivax releases positive top line data from ABX464-005 phase 2a study in HIV infection

    “These findings show, for the first time, that ABX464 has the ability to reduce HIV DNA in both blood and rectal tissue reservoirs,” said Dr Jean-Marc Steens, Chief Medical Officer at ABIVAX. “The longer 12 week duration of treatment with ABX464 was safe and generally well tolerated and supports extended dosing.”

    04 July 2018 | Abivax press release
  • European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

    Today’s decision makes BIC/FTC/TAF Gilead’s third FTC/TAF-based STR approved in the European Union in the past three years.

    25 June 2018 | Gilead press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.